TECHWIRE 30
(CIX: WRAL30)  1,126.59  up arrow+2.55  (0.23 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: Apple)  111.78  down arrow-0.87  (-0.77 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: QUINTILES)  60.39  up arrow+1.01  (1.7 %)  Updated: 06:40 PM EST, Dec 19 2014
(OP: BASF SE)  85.15  down arrow-1.55  (-1.78 %)  Updated: 05:20 PM EST, Dec 19 2014
(NQ: BioCryst)  11.16  up arrow+0.08  (0.68 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: BioDelivery)  13.82  up arrow+0.76  (5.82 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: CEMP)  21.31  up arrow+0.8  (3.9 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: Cisco Systems)  27.77  up arrow+0.12  (0.43 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: Cree)  31.21  up arrow+0.31  (1 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: DARA)  0.88  up arrow+0.04  (4.3 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: EMC CORPORATION)  30.14  up arrow+0.19  (0.63 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: Extreme Networks)  3.44  up arrow+0.09  (2.69 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: FB)  79.88  up arrow+1.48  (1.89 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: GLAXOSMITHKLINE)  43.35  up arrow+0.06  (0.14 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: GOOG)  516.35  up arrow+5.25  (1.03 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: IBM)  158.51  up arrow+0.83  (0.53 %)  Updated: 06:40 PM EST, Dec 19 2014
(NY: LH)  105.80  down arrow-0.64  (-0.6 %)  Updated: 06:40 PM EST, Dec 19 2014
(OP: Lenovo Group)  26.38  up arrow+0.82  (3.21 %)  Updated: 05:20 PM EST, Dec 19 2014
(NY: MRK)  59.58  up arrow+0.6  (1.02 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: Microsoft Corp)  47.66  up arrow+0.14  (0.29 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: NTAP)  42.94  up arrow+0.22  (0.52 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: NOVARTIS AG)  94.61  up arrow+0.04  (0.04 %)  Updated: 06:40 PM EST, Dec 19 2014
(OP: Novozymes A/S)  43.11  down arrow-0.32  (-0.73 %)  Updated: 05:20 PM EST, Dec 19 2014
(NY: PFIZER)  31.94  down arrow-0.03  (-0.09 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: Pozen)  8.17  up arrow+0.27  (3.42 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: RED HAT)  68.04  up arrow+6.54  (10.63 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: BBRY)  9.99  down arrow-0.08  (-0.79 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: Salix)  117.20  down arrow-1.25  (-1.06 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: SQI)  14.97  down arrow-0.09  (-0.6 %)  Updated: 08:10 PM EST, Dec 19 2014

Posts tagged “Scynexis”

Updated May 5

Premium Lock SEVC nearing a sellout with some 50 companies from across region being showcased

The Startup Blog: The Research Triangle will be well represented at the upcoming Southeast Venture Conference in Atlanta with numerous firms already selected to be among the "pitchers" at the two-day event. The event is almost a sellout, according to organizers.

SEVC 2014 SEVC 2014

Updated May 4

Premium Lock A faltering IPO for Scynexis: Shares don't 'pop' but shrink 10%

Scynexis has successfullly priced its shares at $10 for a $62 million IPO, and trading began today. There was no "pop," however. But the IPO occured only after Scynexis management executed a reverse stock split, substantially lowered the options price for some shares, and struck a new credit deal with Sanofi. Trading did not begin Thursday, however.

Scynexis Scynexis

Updated May 2

Premium Lock No IPO yet for Scynexis, which alters offering after reverse stock split, debt deal

Scynexis may finally go public this week after several delays and at a higher stock price. But the IPO will occur only after Scynexis management executed a reverse stock split, substantially lowered the options price for some shares, and struck a new credit deal with Sanofi. Trading did not begin Thursday, however.

Scynexis Scynexis

April 21

Premium Lock Several Triangle firms among 45 'pitchers' at Southeast Venture Conference

The Startup Blog: The Research Triangle will be well represented at the upcoming Southeast Venture Conference in Atlanta with numerous firms already selected to be among the "pitchers" at the two-day event.

SEVC 2014 SEVC 2014

April 21

Premium Lock WSJ: Scynexis is expected to go public today, raise around $50M

The Durham drug-development company was expected to go public earlier this month, but a flagging market apparently set the Scynexis plans back. Now, The Wall Street Journal reports that today is the IPO day.

Scynexis Scynexis

April 8

Premium Lock So when will Scynexis go public? Street sites offer different dates

The Durham drug-development company was expected to go public last week, but those plans were delayed. Now, two Wall Street news sites offer different possibilities for the IPO.

Scynexis Scynexis

April 4

Premium Lock Scynexis IPO delay faces uncertain timetable

The Durham drug-development company was expected to go public this week, but those plans seem to have changed.

Scynexis Scynexis

April 3

Premium Lock Scynexis likely to become latest Triangle IPO today - but at sharply lower price

The Durham-based drug firm has finalized plans to begin selling shares between $7 and $8 on Thursday on the Nasdaq under the symbol SCYX. The nasdaq says the IPO is expected to begin at some point today after trading opens. However, the share price is well under an earlier targeted range of between $12 and $14 a share. Scynexis also is doubling the number of shares available.

The Scynexis pipeline The Scynexis pipeline

April 2

Premium Lock Scynexis sharply lowers target price for stock in IPO, doubles number of shares

The Durham-based drug firm has finalized plans to begin selling shares between $7 and $8 on Thursday on the Nasdaq under the symbol SCYX. That's well under an earlier targeted range of between $12 and $14 a share. Scynexis also is doubling the number of shares available.

Scynexis Scynexis

Updated April 1

Premium Lock Scynexis looks to go public Thursday at $55M

The Durham-based drug firm has finalized plans to begin selling shares between $12 and $14 on Thursday on the Nasdaq under the symbol SCYX. The company does not yet have a drug on the market and lost some $30 million in 2013.

Scynexis Scynexis

Updated March 29

Premium Lock Scynexis lands Russian partner for anti-fungal drug headed for phase II trials

Scynexis The deal expands the market potential for an anti-fungal compound Scynexis originally partnered with Merck. Read about why this drug could have an advantage other anti-fungals in its class.

March 24

Premium Lock Scynexis kicks off 'road show' for its IPO, looks for $12 to $14 per share

Executives from Scynexis are launching their road show today in hopes of generating Wall Street demand for its shares in an initial public offering. The company reaffirms it hopes to sell shares at $12 to $14.

Scynexis Scynexis

Updated March 20

Premium Lock Scynexis looks to raise $68M with IPO

Scynexis In a securities filing on Wednesday, the Durham drug company is looking at the sale of 4.2 million shares in hopes of generating up to $68.1 million with an initial public offering of stock.

Updated March 3

Premium Lock Scynexis files for $55M IPO, banks on antifungal returned by Merck

Scynexis originally partnered with drug giant Merck in 2002 to develop and commercialize a compound called SCY-078. Merck chose to return it last year. Now, Scynexis sees the compound as key to helping it pull off a public offering of stock. It is targeting a $3.6 billion market. So what makes the compound so special?

The Scynexis pipeline The Scynexis pipeline

Updated February 28

Premium Lock IPO Watch: Scynexis joins Square 1 in pipeline of Triangle firms going public

Wall Street Quintiles led the class of Triangle IPOs in the last year at nearly $1 billion in value, but ChannelAdvisor's stock is showing remarkable strength. So is Aerie Pharmaceuticals. With Scynexis filing to go public Thursday, WRALTechWire updates what has happened on the stock "exit route" for regional firms and how their stocks have fared since.

Updated February 26

Premium Lock NC Biotech Center fuels startups with $1.6M in grants, loans

VC funding North Carolina's Biotechnology Center helped fuel the launch and growth of life science startups over the last quarter of 2013 with $1.6 million in grants and loans. Meanwhile, Biotech Center-backed firms raised another $10 million in outside funding.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Scroll